The aim of this study is to compare the efficacy of intralesional bevacizumab, a monoclonal antibody against vascular endothelial growth factor, versus the antiviral drug cidofovir in patients with recurrent respiratory papillomatosis.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Changes in the annual surgery rate
Timeframe: 12 months
Severity of airway affection measured by the Derkay papilloma severity grading scale
Timeframe: 12 months